Source: 6PR Mornings

video

Australian medical bioscientist and clinical immunologist Robert Clancy, an expert in the relationship between infection and the airways, declares “the data is crystal clear, overwhelmingly in support of the fact that ivermectin is of significant benefit when used early in Covid-19 disease.

Despite his understandable reluctance to participate in the inexplicable and ubiquitous politics surrounding these two very safe covid-19 treatments, and his genuine bewilderment at governmental refusal to acknowledge the drugs’ efficacy, the Emeritus Professor was very happy to set the record straight.

The Emeritus Professor quoted ‘incredible meta-analyses, where serious statisticians have put all the studies together and come up with… …an 80% reduction in mortality in people using ivermectin – so conclusive that it was unethical to do further studies involving placebo patients.’

Professor Clancy also clarified that there are several studies on the prophylactic properties of both hydroxychloroquine and ivermectin – a significantly less chance of getting serious covid-19 and dying from it or going to hospital with it.







Related: HCQ Peer-reviewed: Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

Hydroxychloroquine and Ivermectin: The medical establishment’s war on COVID therapeutics

Ivermectin for Covid-19: Database of all Ivermectin COVID-19 studies – 35 trials and growing

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19 infection includes HCQ & Ivermectin

HCQ and Ivermectin included in multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »